Volume 4.30 | Aug 2

Cord Blood News 4.30 August 2, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Microvesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Stimulated by Hypoxia Promote Angiogenesis Both In Vitro and In Vivo
Human umbilical cord-derived mesenchymal stem cells were stimulated by hypoxia and the membrane microvesicles in the supernatants were collected by ultracentrifugation, observed under electron microscope and the origin was identified with flow cytometric technique. [Stem Cells Dev] Abstract

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.
PUBLICATIONS (Ranked by impact factor of the journal)

Amniotic-Fluid-Derived Mesenchymal Stem Cells Overexpressing Interleukin-1 Receptor Antagonist Improve Fulminant Hepatic Failure
Researchers showed that amniotic-fluid-derived mesenchymal stem cells genetically modified to over-express interleukin-1-receptor antagonist can be implanted into the injured liver to provide a novel therapeutic approach to the treatment of fulminant hepatic failure. [PLoS One] Full Article

In Vitro Endothelialization of Electrospun Terpolymer Scaffolds: Evaluation of Scaffold Type and Cell Source
A family of methacrylic terpolymer biomaterials was electrospun into three-dimensional scaffolds. Three different endothelial-like cell populations were seeded onto the scaffolds under static conditions: human umbilical vein endothelial cells, adult human blood-derived outgrowth endothelial cells, and umbilical cord blood-derived human blood outgrowth endothelial cells. Researchers observed difference in cellular behavior based on both cell type and scaffold topography. [Tissue Eng Part A] Abstract

Comparative In Vitro Analysis of Different Hematopoietic Cell Populations from Human Cord Blood: In Search of the Best Option for Clinically Oriented Ex Vivo Cell Expansion
Investigators obtained different hematopoietic cell populations from umbilical cord blood and simultaneously assessed their proliferation and expansion kinetics. Their main goal was to determine which one of these cell populations would be more suitable for clinical-grade ex vivo expansion. [Transfusion] Abstract

Interactions of Monocyte Subpopulations Generated from Cord Blood CD34+ Hematopoietic Progenitors with Tumor Cells: Assessment of Antitumor Potential
Monocytes and their subsets generated from cord blood CD34+ progenitor cells were used for determination of their capacity to interact with tumor cells in vitro and in vivo. [Exp Hematol] Abstract

CD26 Protease Inhibition Improves Functional Response of Un-Fractionated Cord Blood, Bone Marrow, and Mobilized Peripheral Blood Cells to CXCL12/SDF-1
Researchers observed that although cord blood (CB) had greater CD26 expression than bone marrow or mobilized peripheral blood (mobPB), treatment with a CD26 inhibitor resulted in increased responsiveness to SDF-1 for all three MNC sources tested. This suggests that clinical therapeutic benefit may be gained by utilizing CD26 inhibitors as a strategy to improve engraftment of un-fractionated mobPB cells as well as CB cells. [Exp Hematol] Abstract

Growth and Differentiation Characteristics of Equine Mesenchymal Stromal Cells Derived from Different Sources
Investigators compared clinically relevant characteristics of mesenchymal stromal cells derived from bone marrow, umbilical cord blood and tissue and from adipose tissue and tendon. Cell yield, proliferation, migration, tendon marker expression and differentiation into adipocytes, chondrocytes and osteoblasts was assessed, quantified and compared. [Vet J] Abstract

Increased Reticulocyte Count from Cord Blood Samples Using Hypotonic Lysis
Scientists describe a simple and inexpensive method to increase the reticulocyte count of cord blood samples. [Exp Parasitol] Abstract

Superior Osteogenic Capacity of Different Mesenchymal Stem Cells for Bone Tissue Engineering
Results suggested that human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and human adipose tissue-derived mesenchymal stem cells could be used for bone tissue engineering effectively; hUC-MSCs could serve as a new alternative cell source. [Oral Surg Oral Med Oral Pathol Oral Radiol] Abstract

Learn more about the new smartphone app for human blood cell frequencies


NEW: StemSpan™ ACF, the First Plasma Component-Free Hematopoietic Expansion Media
STEMCELL Technologies Inc. announced the launch of StemSpan™ ACF, a new animal component-free (ACF) and chemically-defined hematopoietic stem cell expansion medium, which contains no animal and human plasma-derived components. [STEMCELL Technologies Inc.] Press Release

Stem Cell Agency Commits $150 Million to Develop New Therapies
California’s stem cell agency, the California Institute for Regenerative Medicine approved $150 million in new funding to help move promising stem cell-based therapies from the laboratory research phase to clinical trials in people. [California Institute for Regenerative Medicine] Press Release


U.S. Federal Court Says Stem Cell Treatments Are Drugs
A U.S. federal court has found that a stem cell therapy offered by a Colorado clinic meets the definition of a regulated drug. The ruling could spur a U.S. Food and Drug Administration crackdown on other clinics offering untested adult stem cell treatments in the United States. [U.S. District Court for the District of Columbia, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 8th World Stem Cell Summit
December 3-5, 2012
West Palm Beach, United States

our events page to see a complete list of events in the cord blood community.

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Stem Cell Therapy Scientist (Paramount Recruitment)

Clinical Lab Scientist – Cord Blood (Cardinal Glennon Children’s Medical Center)

Postdoctoral Position – Molecular Biology (Faculty of Informatics, Masaryk University)

Postdoctoral Position – Stem Cell Research (Connecticut Children’s Medical Center, University of Connecticut)

Postdoctoral Fellow – Stem Cell Biology and Developmental Hematopoiesis (Mount Sinai School of Medicine)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us